Evidence map›Paper›PMID 40006574›Full record

ReviewPharmaceutics2025

Nanostructured Formulations for a Local Treatment of Cancer: A Mini Review About Challenges and Possibilities.

Tatiane Roquete Amparo, Tamires Cunha Almeida, Lucas Resende Dutra Sousa, Viviane Flores Xavier, Glenda Nicioli da Silva, Geraldo Célio Brandão, Orlando David Henrique Dos Santos

Abstract readReview
In one paragraph

Review in Pharmaceutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Tatiane Roquete AmparoDepartment of Pharmacy, Federal University of Ouro Preto, Rua Professor Paulo Magalhães Gomes, 122-Bauxita, Ouro Preto 35400-000, Brazil.ORCID 0000-0002-6426-7113
Tamires Cunha AlmeidaLaboratory of Pain and Signaling, Butantan Institute, Av. Vital Brasil, 1500-Butantã, São Paulo 05503-900, Brazil.ORCID 0000-0002-5584-3609
Lucas Resende Dutra SousaDepartment of Pharmacy, Federal University of Ouro Preto, Rua Professor Paulo Magalhães Gomes, 122-Bauxita, Ouro Preto 35400-000, Brazil.ORCID 0000-0003-2408-3448
Viviane Flores XavierDepartment of Pharmacy, Federal University of Ouro Preto, Rua Professor Paulo Magalhães Gomes, 122-Bauxita, Ouro Preto 35400-000, Brazil.
Glenda Nicioli da SilvaDepartment of Pharmacy, Federal University of Ouro Preto, Rua Professor Paulo Magalhães Gomes, 122-Bauxita, Ouro Preto 35400-000, Brazil.ORCID 0000-0001-9751-3379
Geraldo Célio BrandãoDepartment of Pharmacy, Federal University of Ouro Preto, Rua Professor Paulo Magalhães Gomes, 122-Bauxita, Ouro Preto 35400-000, Brazil.ORCID 0000-0002-7330-051X
Orlando David Henrique Dos SantosDepartment of Pharmacy, Federal University of Ouro Preto, Rua Professor Paulo Magalhães Gomes, 122-Bauxita, Ouro Preto 35400-000, Brazil.ORCID 0000-0002-8904-6990

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer represents a significant societal, public health, and economic challenge. Conventional chemotherapy is based on systemic administration; however, it has current limitations, including poor bioavailability, high-dose requirements, adverse side effects, low therapeutic indices, and the development of multiple drug resistance. These factors underscore the need for innovative strategies to enhance drug delivery directly to tumours. However, local treatment also presents significant challenges, including the penetration of the drug through endothelial layers, tissue density in the tumour microenvironment, tumour interstitial fluid pressure, physiological conditions within the tumour, and permanence at the site of action. Nanotechnology represents a promising alternative for addressing these challenges. This narrative review elucidates the potential of nanostructured formulations for local cancer treatment, providing illustrative examples and an analysis of the advantages and challenges associated with this approach. Among the nanoformulations developed for the local treatment of breast, bladder, colorectal, oral, and melanoma cancer, polymeric nanoparticles, liposomes, lipid nanoparticles, and nanohydrogels have demonstrated particular efficacy. These systems permit mucoadhesion and enhanced tissue penetration, thereby increasing the drug concentration at the tumour site (bioavailability) and consequently improving anti-tumour efficacy and potentially reducing adverse effects. In addition to studies indicating chemotherapy, nanocarriers can be used as a theranostic approach and in combination with irradiation methods.

Indexed as

cancerlocal treatmentnanoformulationsnanotechnology

Identifiers

PMID40006574
PMCPMC11859672

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.